Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory DLBCL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03255096
What this trial is testing

Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Who this might be right for
Diffuse Large B-cell LymphomaHigh-Grade B-cell Lymphoma
Hoffmann-La Roche 39
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Testing effectiveness (Phase 2)Ended earlyNCT05896163
What this trial is testing

Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 40
Not applicableStudy completedNCT00301301
What this trial is testing

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Non-Hodgkins Lymphoma
Royal Marsden NHS Foundation Trust 39
Testing effectiveness (Phase 2)Study completedNCT01523834
What this trial is testing

Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT

Who this might be right for
Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS 35
Testing effectiveness (Phase 2)Ended earlyNCT03135262
What this trial is testing

Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Follicular LymphomaLymphoma, Large B-Cell, Diffuse
Hoffmann-La Roche 29
Testing effectiveness (Phase 2)Looking for participantsNCT06649812
What this trial is testing

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type+12 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT01078922
What this trial is testing

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Who this might be right for
Non-Hodgkin Lymphomas
Oncology Specialists, S.C. 11
Testing effectiveness (Phase 2)Ended earlyNCT02568683
What this trial is testing

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non-Hodgkin Lymphoma
Gilead Sciences 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10
Early research (Phase 1)Study completedNCT02471911
What this trial is testing

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Weill Medical College of Cornell University 22
Testing effectiveness (Phase 2)UnknownNCT01653067
What this trial is testing

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Mathias Witzens-Harig 88
Testing effectiveness (Phase 2)UnknownNCT01676558
What this trial is testing

A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma
Korea Cancer Center Hospital 24
Not applicableApproved For MarketingNCT04300803
What this trial is testing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Who this might be right for
DLBCL
MorphoSys AG
Testing effectiveness (Phase 2)Study completedNCT02674750
What this trial is testing

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

Who this might be right for
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Curis, Inc. 70
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics Incorporated 86
Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85
Early research (Phase 1)Study completedNCT01742988
What this trial is testing

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Who this might be right for
LymphomaRelapsed LymphomaRefractory Lymphoma+8 more
Curis, Inc. 106
Testing effectiveness (Phase 2)Study completedNCT02399085
What this trial is testing

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
MorphoSys AG 81
Early research (Phase 1)Active Not RecruitingNCT05512390
What this trial is testing

Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Diffuse Large B-Cell LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma
AbbVie 39
Next Page
120